San Diego – April 20, 2017 – Cooley advised Tocagen on its $97.8 million initial public offering of 9,775,000 shares of common stock.

San Diego-based Tocagen, which trades on The NASDAQ Global Select Market as “TOCA,” is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.